Apicore (RK Pharma)
Apicore (RK Pharma) is a peptide CDMO based in USA (East Windsor, NJ). Direct manufacturer. Holds US DMFs for semaglutide, tirzepatide, cetrorelix, degarelix and 2 more API.
Listing reviewed October 2026.
About Apicore (RK Pharma)
Process R&D and API manufacturing company in East Windsor, New Jersey, wholly owned by RK Pharma, which describes itself as specializing in peptides and also operates Apicore Pharmaceuticals in India. The East Windsor site was classed NAI at FDA inspections in 2017, 2019 and 2025. Holds active US Drug Master Files for cetrorelix, degarelix, ganirelix, semaglutide, tirzepatide and vosoritide API.
Directory assessment: Apicore (RK Pharma) is listed as a CDMO in the peptide supply chain, serving North America markets from USA (East Windsor, NJ). As a direct manufacturer, this supplier controls its own production process from synthesis through purification and quality control release testing. This profile lists 4 sources for reference. This supplier has a strong confidence score, indicating a high level of verification and reliability for B2B sourcing.
- Cetrorelix: DMF 41854 (Type II, active), submitted 2025-05-30
- Degarelix: DMF 40970 (Type II, active), submitted 2024-12-28
- Ganirelix: DMF 36902 (Type II, active), submitted 2022-04-28
- Semaglutide: DMF 40124 (Type II, active), submitted 2024-06-29
- Tirzepatide: DMF 40123 (Type II, active), submitted 2024-07-27
- Vosoritide: DMF 42084 (Type II, active), submitted 2025-07-30
DMF numbers from the FDA quarterly DMF list. A filed DMF is not FDA approval; its contents are confidential. Reviewed 2026-10-23.